ALAMEDA, Calif.--(EON: Enhanced Online News)--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is delivering a presentation at the Global Bioproduction Summit, December 12-13, at the Hilton San Diego Bayfront.
“Methodologies for Human Cell Manufacturing from Pluripotent Stem Cells in the Application of Regenerative Medicine”
Dr. West’s presentation, “Methodologies for Human Cell Manufacturing from Pluripotent Stem Cells in the Application of Regenerative Medicine,” will be delivered on Tuesday, December 13, at 9:20 a.m. PST and will cover the following topics:
- Where are we going wrong? – Contrasting the scale-up manufacturing of adult cells versus pluripotent cells, and analysing the advantages and disadvantages of both
- A look into novel technologies for the reproducible manufacturing of 1st & 2nd generation, highly-identified, purified products derived from pluripotent stem cells
- Case Study – the unique phenotype of pluripotent-stem-cell-derived cells that could improve the process of tissue repair
A copy of Dr. West’s presentation will be made available on the BioTime website.
BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what the company believes to be the world’s premier collection of pluripotent cell assets. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.